A Phase I, First-In-Human, Randomized, Double-blind, Placebo-controlled, Single-Ascending-Dose Study of TT-00920 in Healthy Subjects
Latest Information Update: 01 Mar 2023
At a glance
- Drugs TT 00920 (Primary)
- Indications Chronic heart failure
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors TransThera Biosciences
- 24 Feb 2023 Status changed from active, no longer recruiting to completed.
- 26 Oct 2021 Planned End Date changed from 28 Feb 2021 to 30 Nov 2021.
- 26 Oct 2021 Status changed from recruiting to active, no longer recruiting.